AstraZeneca

AstraZeneca PLC[1], is a large Anglo-Swedish pharmaceutical company formed on 6 April 1999 by the merger of Swedish Astra AB and British Zeneca Group PLC. Zeneca was part of Imperial Chemical Industries prior to a demerger in 1993.[2][3] AstraZeneca develops, manufactures, and sells pharmaceuticals to treat disorders in the gastrointestinal, cardiac and vascular, neurological and psychiatric, infection, respiratory, pathological inflammation and oncology areas.

Sales in 2003 totalled $18.8 billion, with a profit before tax of $4.2 billion. Total R&D spending was $3.5 billion. The corporate headquarters are in London, UK, the research and development (R&D) headquarters are in Södertälje, Sweden. Major R&D centres are located on three continents in the United States, United Kingdom, Sweden, and India.

The current chief executive of AstraZeneca is Sir Tom McKillop. It has been announced that McKillop will be retiring from the CEO role as of 1st Jan 2006 to be replaced by David Brennan.[4]

Profiles
Yahoo profile

Diversity
AstraZeneca is one of the 100 Best Companies for Working Mothers in 2004 according to Working Mothers magazine.[5]

Products
AstraZeneca specialises in prescription medicines to fight disease in the several therapeutic areas. Year-on sales information can be found through AstraZeneca annual reports. The following is a list of key products as found on the AstraZeneca US website, retrieved 2005-03-27.

This list is incomplete; you can help by expanding it.
Gastrointestinal
Entocort
Losec/Prilosec
Nexium (purified stereoisomer of Losec)
Cardiovascular
Atacand
Crestor (2003 launch)
Exanta (2004 launch; not approved in the United States)
Imdur
Indural
Lexxel
Logimax
Nif-Ten
Plendil
Ramace
Seloken ZOK/Toprol-XL (#1 beta blocker by sales globally in 2004)
Tenoretic
Tenormin
Unimax
Zestoretic
Zestril
Respiratory and Inflammation
Accolate
Bambec
Bricanyl
Oxis
Pulmicort
Rhinocort
Symbicort
Oncology
Arimidex
Casodex
Faslodex
Iressa
Nolvadex
Tomudex
Zoladex
in development
Zactima (Phase III clinical trial - Press release)
Neuroscience
Indural
Mysoline (handed over to Acorus Therapeutics Ltd. in July of 2004)
Seroquel
Vivalan
Zomig
Anaesthetics
Carbocaine
Citanest
Diprivan
EMLA (mixture of Lidocaine and Prilocaine)
Marcaine/Sensorcaine
Naropin
Xylocaine
Infection
Apatef/Cefotan
Merrem/Meronem

Controversy over Nexium
Nexium, the successor to Prilosec, has according to some commentators "become a symbol of everything that is wrong with the pharmaceutical industry".[6]

Collaborations and alliances
references in this section appear here rather than as endnotes and should be press releases from one or more of the partners; there should be only one entry for each collaboration and only one informational reference in order to maintain a brief yet informative list

Astex. Announced 2005. For discovery, development and commercialisation of novel small molecule inhibitors of Protein Kinase B for use as anti-cancer agents. Press release
Avanir. Announced 2005. For research and licensing in the area of Reverse Cholesterol Transport (RCT) enhancing compounds for the treatment of cardiovascular disease. Press release
Cambridge Antibody Technology. Announced 2004. For monoclonal antibody research, in the area of inflammatory disorders, including respiratory diseases. Press release.
Schering AG. Announced 2005. For research and licensing in the area of Selective Glucocorticoid Receptor Agonists (SEGRAs).

AstraZeneca of PLC[1], is a large astrazeneca Anglo-Swedish astrazeneca pharmaceutical company number formed on 6 April 1999 by the disease merger of Swedish Astra AB and British node Zeneca Group PLC. discover version Zeneca sales was part of Imperial assistance marketing Chemical Industries prior to today a demerger prescription in 1993.[2][3] AstraZeneca develops, manufactures, and astrazeneca sells pharmaceuticals to astrazeneca treat disorders in
the gastrointestinal, cardiac and vascular, astrazeneca astrazeneca neurological and psychiatric, infection, respiratory, pathological pharmaceutical inflammation and oncology areas.

Sales med in 2003 totalled $18.8 billion, with astrazeneca a profit before patient
tax of your.az $4. 2 astrazeneca billion. Total R&D spending was and $3.5
billion. The corporate astrazeneca headquarters
are in London, UK, the research
uk
and development (R&D) astrazeneca
doug aid headquarters astrazeneca are in Södertälje, Sweden. page Major astrazeneca R&D centres are located on three continents in the United drug States, samples United Kingdom, Sweden, and lp India.

The current chief executive of AstraZeneca is Sir Tom McKillop. It has been announced that McKillop will be retiring size from the astrazeneca CEO role
as of 1st Jan 2006 to directors astrazeneca be replaced by David Brennan.phone [4]

astrazeneca pharmaceuticals

Profiles
Yahoo profile

sales illinois
taxonomy Diversity
AstraZeneca propofol is one of the canada astrazeneca 100 Best Companies for lung Working sales Mothers
in 2004 service inc. according to Working canada Mothers magazine.[5]

Products
AstraZeneca specialises astrazeneca in prescription medicines to astrazeneca fight disease in program the several
therapeutic areas. Year-on sales information can be found through AstraZeneca annual reports. The following is biomarker a director list of key products as found on the pharmacuticals AstraZeneca
US website, and retrieved 2005-astrazeneca 03-27.

This list is patient incomplete; chronic pharmaceuticals you can help by expanding it.
Gastrointestinal
Entocort
Losec/Prilosec
Nexium ( purified stereoisomer of assistance Losec)
spend Cardiovascular
Atacand
Crestor (2003 launch)
uk
Exanta (2004 launch; not approved
in the phoenix
United States)
Imdur
Indural
Lexxel

Logimax
Nif- Ten
Plendil
Ramace
Seloken ZOK/Toprol-XL (
#1 beta blocker by astrazeneca sales astrazeneca globally bertil in astrazeneca 2004)
Tenoretic
Tenormin
e.g
Unimax
Zestoretic
Zestril
Respiratory and 2005

Inflammation
Accolate
Bambec
Bricanyl
Oxis
Pulmicort
Rhinocort
Symbicort
bartels
contacts canada Oncology
Arimidex
Casodex
uniqema inc. Faslodex
Iressa

service Nolvadex
Tomudex
Zoladex
in development
us-de-delaware Zactima ( Phase
grants III astrazeneca clinical trial - Press release)
Neuroscience
Indural
Mysoline (handed over to Acorus Therapeutics Ltd. in July of 2004)
astrazeneca and Seroquel

Vivalan
Zomig
Anaesthetics
copd Carbocaine
Citanest
Diprivan
EMLA (mixture of Lidocaine and Prilocaine)
Marcaine/Sensorcaine
Naropin
august Xylocaine
Infection
astrazeneca contact astrazeneca Apatef/Cefotan
Merrem/Meronem

Controversy over ltd
Nexium
Nexium, the successor to Prilosec, has according grants to some commentators "become a pharmaceuticals, symbol
scholarships of home everything that is wrong with educations v.
the pharmaceutical industry".[6]

program Collaborations astrazeneca
and alliances

oncology references samples in this lindmark section appear here astrazeneca rather than as endnotes and should be press releases from
one or more of the partners; there should be only astrazeneca one
scholarships entry for each
collaboration astrazeneca and only one informational reference in order to maintain a housey brief yet informative list

Astex. Announced
2005. For pharmaceutical discovery, astrazeneca
development and commercialisation of novel small molecule taxonomy inhibitors astrazeneca
of Protein Kinase B for use as anti-3 cancer agents. Press release
Avanir. Announced clarification 2005. For research and licensing astrazeneca in the area astrazeneca of Reverse merck Cholesterol Transport (RCT) enhancing compounds for the force treatment your.az of scandel cardiovascular donations disease. Press release
Cambridge Antibody Technology. Announced 2004. For monoclonal astrazeneca antibody research, in copyright astrazeneca
the area of inflammatory disorders, including respiratory sex diseases. Press release.
Schering AG. Announced 2005. For research astrazeneca and licensing in the
area of Selective astrazeneca Glucocorticoid Receptor schedules sverige Agonists (SEGRAs). astrazeneca company

Information provided by Wikipedia.